Application
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using PTEN Antibody (left) or the same antibody preincubated with blocking peptide (right).Application
Western blot analysis of extracts from HT29 cells using PTEN Antibody and the same antibody preincubated with blocking peptide.Application
Western blot analysis of extracts from HT29 cells using PTEN(Ab-380/382/383) Antibody and the same antibody preincubated with blocking peptide.| Product Name | PTEN antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit Polyclonal antibody to PTENTumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. |
| Immunogen | Peptide sequence around aa.378~382/380~384/381~385 (R-Y-S-D-T-T-D-S) derived from Human PTEN. |
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Tested Applications | IHC-PWB |
| Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml (Please refer to the vial label for the specific concentration) |
| Purification | Affinity purified |
| Gene Synonyms | 10q23del BZS DEC GLM2 MGC11227 MHAM MMAC1 PTEN1 TEP1 PTEN mutated in multiple advanced cancers 1 phosphatase and tensin-like protein phosphatidylinositol-3 4 5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN MMAC1 pho |
|---|---|
| Target | PTEN |
| Molecular Weight(MW) | 54 (note) |
Application
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using PTEN Antibody (left) or the same antibody preincubated with blocking peptide (right).
Application
Western blot analysis of extracts from HT29 cells using PTEN Antibody and the same antibody preincubated with blocking peptide.
Application
Western blot analysis of extracts from HT29 cells using PTEN(Ab-380/382/383) Antibody and the same antibody preincubated with blocking peptide.| Application Notes | Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
